-
Staidson Pharmaceutical Plans RMB 580 Million Private Placement for Drug R&D
•
China-based Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204) has announced plans to raise RMB 580 million (USD 84.1 million) through a private placement, with the net proceeds designated for innovative drug research and development (R&D). This move follows previous unsuccessful attempts to raise funds through private placements of RMB 1.08…
-
Sangon Biotech Secures RMB 2 Billion in First Financing Round to Boost Life Science Services
•
China-based contract research organization (CRO) Sangon Biotech has secured RMB 2 billion (USD 290.3 million) in its first financing round, led by GL Capital. Joining the round are CITIC Private Equity, Greenwoods Investment, Huagai Capital, and Guokai Technology Venture Investment. This significant funding will enable Sangon to accelerate human resource…
-
Shenzhen 01 Life Science Secures RMB 100 Million in Series B1 Financing for Microecology Platform
•
Shenzhen 01 Life Science and Technology Ltd. Co., Ltd, a company specializing in human big data-driven microecology high-throughput screening and application transformation, has reportedly raised RMB 100 million (USD 14.5 million) in a Series B1 financing round. The investors in this round include Green Pine Capital Partners, Seas Capital, Green…
-
Pfizer’s Prevenar 13 Receives Expanded Age Range Approval in China
•
U.S.-based pharmaceutical giant Pfizer (NYSE: PFE) has reported receiving an additional indication approval from the National Medical Products Administration (NMPA) for its globally successful vaccine, Prevenar 13. The approval extends the vaccine’s use to infants and children aged between 6 weeks to 5 years (before the 6th birthday), expanding the…
-
BeiGene’s Tislelizumab-Chemo Combo Excels in RATIONALE 305 Trial for Gastric Cancer
•
BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235), a China-based biopharmaceutical company, has announced that the global RATIONALE 305 trial has successfully met its primary endpoint of overall survival. The trial demonstrated that tislelizumab, in combination with chemotherapy, showed superior overall survival (OS) compared to chemotherapy alone in patients with advanced…
-
Zylox-Tonbridge Medical Teams Up with Hicicare Science for Guide Wire Product Sales in China
•
China-based nerve and peripheral vascular interventional device developer Zylox-Tonbridge Medical Technology (HKG: 2190) has announced a strategic partnership with Guangdong Hicicare Science Co., Ltd. The collaboration aims to promote and sell Zylox-Tonbridge’s peripheral vascular intervention and neurovascular intervention guide wire products in China. Financial details of the agreement were not…
-
Shanghai Ark Biopharmaceutical’s STAR Market IPO Filing Accepted, Aims to Raise $289.6 Million
•
Shanghai Ark Biopharmaceutical Co., Ltd’s Initial Public Offering (IPO) filing to the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR) has been accepted for review by the exchange, with expectations to raise RMB 1.997 billion (USD 289.6 million). This move follows the company’s previous withdrawal of an IPO filing in Hong…
-
Hunan Warrant Pharmaceutical Receives NMPA Approval for Generic Brivudine
•
Hunan Warrant Pharmaceutical Co., Ltd (SHA: 688799), a China-based pharmaceutical company, has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its generic version of Menarini’s brivudine. This approval signifies that Warrant Pharma’s version of the drug has successfully passed the generic quality consistency evaluation (GQCE) and…
-
Junshi Biosciences’ Tuoyi Combo Shows Promise in Phase III Neotorch Study for NSCLC
•
China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has published the results of the Phase III Neotorch study for its programmed death-1 (PD-1) inhibitor Tuoyi (toripalimab) combined with chemotherapy for the perioperative treatment of resectable non-small cell lung cancer (NSCLC) at the American Society of Clinical Oncology (ASCO) Plenary Series this…
-
Jiangsu Aidea Pharmaceutical Secures Global Licensing Deal for Kainos Medicine’s HIV Drugs
•
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a China-based pharmaceutical company, has entered into a licensing agreement with South Korean firm Kainos Medicine Inc., concerning Kainos’ ainuovirine (ACC007) and its fixed dose preparation ainuovirine, lamivudine, tenofovir disoproxil (ACC008). The agreement grants Aidea commercial, development, and promotion rights for these drugs…
-
Acotec Scientific’s Vericor-14 Microcatheter Receives NMPA Approval for Vascular Surgeries
•
China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its Vericor-14 microcatheter. The product is now approved for use in percutaneous intervention surgery of coronary arteries and peripheral blood vessels, providing targeted access to the lesion site of narrow…
-
Janssen’s Spravato Approved by NMPA for Adult Depression and Suicidal Ideation Treatment
•
Janssen’s Spravato (esketamine) has been granted approval by the National Medical Products Administration (NMPA) in China for the alleviation of depressive symptoms in adult patients with acute suicidal ideation or behavior when used in combination with an oral antidepressant. Spravato: A Novel Antidepressant with Rapid-Onset ActionSpravato marks a significant advancement…
-
Jiangxi Jemincare Group Secures Clinical Trial Approvals for Four Innovative Drugs
•
Jiangxi Jemincare Group, a China-based pharmaceutical company, has announced receiving clinical trial approvals for four category 1 innovative drugs. Three of these approvals were granted by the National Medical Products Administration (NMPA) in China, and one by the US FDA. The drugs are targeted towards treating kidney and cardiovascular diseases.…
-
CSPC Pharmaceutical Group Gets NMPA Approval for SYS6010 ADC Clinical Trial
•
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its antibody-drug conjugate (ADC), SYS6010, which is intended for the treatment of advanced solid tumors. Pre-Clinical Studies and Patent Protection for SYS6010Pre-clinical studies have demonstrated that…
-
Legend Biotech’s Carvykti Data Boosts Stock Price by 19.64% on Positive Phase III Results
•
Shares of Legend Biotech (NASDAQ: LEGN) jumped an impressive 19.64% in a single day, attributed by industry media to the recent leak of positive data from the ongoing Phase III CARTITUDE-4 study. The study is assessing Legend’s BCMA-targeted chimeric antigen receptor (CAR) T cell therapy, Carvykti (ciltacabtagene autoleucel), as a…
-
Acotec Scientific Holdings Receives NMPA Approval for Paclitaxel-Coated Balloon Dilation Catheter
•
China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving marketing approval from the National Medical Products Administration (NMPA) for its paclitaxel-coated arteriovenous fistula high-pressure balloon dilation catheter, ACOART AVENS. The product is intended for use in percutaneous transluminal angioplasty (PTA) for autologous arteriovenous fistula stenosis in hemodialysis patients. Product…
-
CARSgen Therapeutics’ CT041 Receives NMPA Approval for Post-Operative Pancreatic Cancer Therapy
•
China-based chimeric antigen receptor (CAR)-T cell specialist, CARSgen Therapeutics Holdings Ltd (HKG: 2171), has announced receiving clinical trial approval from the National Medical Products Administration (NMPA) for its pipeline candidate, CT041. The therapy will be assessed as a post-operative adjuvant treatment for Claudin18.2 (CLDN18.2)-positive pancreatic cancer. Potential First-In-Class CAR-T Therapy:…
-
Zelgen Biopharmaceuticals’ ZG2001 Receives NMPA Approval for Clinical Trials
•
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 product candidate, ZG2001. ZG2001: An Oral Pan-KRAS Mutation InhibitorZG2001, an in-house developed oral pan-KRAS mutation inhibitor, is under development for the treatment of…
-
Beijing Aosaikang’s ASKG915 Receives NMPA Approval for Clinical Trials in Advanced Solid Tumors
•
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced receiving clinical trial approval for its Category 1 biologic product ASKG915 from the National Medical Products Administration (NMPA). The study will initially assess the therapy in patients with general advanced solid tumors. ASKG915: A Bifunctional Fusion Protein Targeting PD-1 and IL-15ASKG915…
-
InnoCare Pharma’s Orelabrutinib Gains NMPA Approval for Recurrent/Refractory MZL Treatment
•
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving another indication approval from the National Medical Products Administration (NMPA) for its Bruton’s tyrosine kinase (BTK) inhibitor, orelabrutinib. The drug can now be used to treat recurrent/refractory marginal zone lymphoma (MZL), marking it as the first BTK inhibitor for that…
